# Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment

> **NCT03309202** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** PF-05221304

## Key facts

- **NCT ID:** NCT03309202
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-19
- **Primary completion:** 2018-06-26
- **Final completion:** 2018-07-18
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03309202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03309202, "Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03309202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*